21 results on '"Mazulov O"'
Search Results
2. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency
- Author
-
Miravitlles, M., Chorostowska-Wynimko, J., Ferrarotti, I., McElvaney, N.G., O'Hara, K., Stolk, J., Stockley, R.A., Turner, A., Wilkens, M., Greulichon, T., Corsico, A., Corda, L., Sucena, M., Barrecheguren, M., Esquinas, C., Parr, D., Lara, B., Mahadeva, R., Chlumsky, J., Janciauskiene, S., Bals, R., Seersholm, N., Kohler, M., Clarenbach, C., Altraja, A., Jenssens, W., Gouder, C., Hecimovic, A., Dudvarski, A., Krams, A., Ulmeanu, R., Zaharie, A., Mornex, J.F., Yorgancioglu, A., Schmid-Scherzer, K., Tanash, H., Mazulov, O., Ivanov, Y., and EARCO Clinical Res Collaboration
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Biomedical Research ,International Cooperation ,Alpha (ethology) ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,alpha 1-Antitrypsin Deficiency ,Pulmonary Medicine ,Medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Registries ,Program Development ,Alleles ,International research ,Alpha 1-antitrypsin deficiency ,business.industry ,medicine.disease ,Europe ,Clinical research ,Phenotype ,030228 respiratory system ,alpha 1-Antitrypsin ,business - Abstract
The European Alpha-1 Research Collaboration (EARCO) will promote international research in alpha-1 antitrypsin deficiencyhttp://ow.ly/DWwg30nwCj4
- Published
- 2019
3. Genes Polymorphism Of Surfactant Protein B And Respiratory Morbidity In Preschoolers
- Author
-
Mazulov, O. and Yablon, O.
- Subjects
lcsh:Sports ,surfactant protein b ,lcsh:GV557-1198.995 ,lcsh:R ,preschoolers ,lcsh:Medicine ,lcsh:L ,respiratory morbidity ,polymorphism ,lcsh:Education - Abstract
Mazulov O., Yablon O. Genes polymorphism of surfactant protein B and respiratory morbidity in preschoolers. Journal of Education, Health and Sport. 2017;7(6):635-643. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.834739 http://ojs.ukw.edu.pl/index.php/johs/article/view/4651 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Author 2017; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 03.06.2017. Revised: 20.06.2017. Accepted: 30.06.2017. Genes polymorphism of surfactant protein B and respiratory morbidity in preschoolers O. Mazulov, O. Yablon Vinnytsya Pirogov Medical University, Ukraine, Vinnitsa Abstract There was a prospective single-center study of 50 prematurely born children (25 males and 25 females, mean gestational age 31.6 ± 2.6 weeks, mean body weight at birth 1743.4 ± 454.3 g) conducted in Vinnytsya Children’s Regional Hospital during 2010-2015. At the age of 5.2 ± 0.7 years children were divided on a several groups: children diagnosed with asthma - 9 (18%), children diagnosed with recurrent episodes of obstructive bronchitis (recurrent wheezing) - 18 (36%), children diagnosed with bronchopulmonary dysplasia - 8 (16%) and 15 children without respiratory diseases (30%). As a result of Single nucleotide polymorphism (SNP) investigation in surfactant protein B C1580T locus a several sequences were evaluated and explored: CC in 17 (34%) of patients, a TT sequence of nucleotides in 12 (24%) of patients, and CT nucleotide sequence was observed in 21 (42%) children. Odds ratio found that the nucleotide sequence CC might be a predictive value of recurrent bronchial obstructions, nucleotide sequence TT more often observed in patients with asthma, and the presence of CT nucleotide sequence in polymorphic locus of gene of surfactant protein B C1580T might have a positive prognostic value regarding the absence of chronic bronchopulmonary diseases in children. Keywords: polymorphism; surfactant protein B; respiratory morbidity; preschoolers.
- Published
- 2017
- Full Text
- View/download PDF
4. SURFACTANT PROTEIN B LEVEL IN SERUM OF PRETERM NEONATES AS MARKER OF DAMAGE OF RESPIRATORY TRACT
- Author
-
Mazulov, O.
- Subjects
новорожденные ,сурфакта-нтный протеин В ,новонароджені ,сурфактантний протеїн В ,newborn ,surfactantprotein B - Abstract
Вступ. Білкові компоненти сурфактанту є необхідними та функціонально ефективними його частинами. Найбільший науковий інтерес серед сурфактантних протеїнів викликає вивчення сурфактантного протеїну B. Основними його функціями є сприяння підвищенню поверхневого натягу в альвеолах, протизапальні та антиоксидантні властивості. Але остаточні уявлення щодо його фізіологічної ролі та вмісту при різних патологічних станах ще не сформовані.Матеріали та методи дослідження.Обстежено 58 новонароджених дітей, з них 42 недоношених дити-ни, які мали патологію дихальної системи в неонатальному періоді, з середнім гестаційним віком 32,18 ± 1,4 тижні, середньою вагою при народженні 1919,1±123,4 г та 16 доношених новонароджених. Вміст сурфактантного протеїну В у сироватці крові визначали на 3-5 день життя імуноферментним методом за набором «Human HSP-27/HSPB1 (HeartShockProtein 27) ELISAkit»(Elabscience) у відповідності до інструкції фірми-виробника.Результати та обговорення.Дослідження рівня SP-B в сироватці крові дітей основної групи показало його достовірно вищий вміст, який склав в середньому 58,5 ± 5,4 нг/мл, тоді як у дітей контрольної групи середнє значення було 22,06 ± 2,3 нг/мл (p, Введение.Белковые компоненты сурфактанта явля-ються необходимыми и функционально эффективными его частями. Наибольший научный интерес среди сурфактантных протеинов вызывает изучение сур-фактантного протеина B. Основными его функция-ми являются содействие повышению поверхностно-го натяжения в альвеолах, противовоспалительные и антиоксидантные свойства. Однако окончательные представления о его физиологической роли и содержа-нии при различных патологических состояниях еще не до конца сформированы.Материалы и методы исследования. Обсле-довано 58 новорожденных детей, из них 42 недо-ношенных новорожденных, которые имели патоло-гию дыхательной системы в неонатальном периоде, со средним гестационным возрастом 32,18 ± 1,4 неде-ли, средним весом при рождении 1919,1 ± 123,4 г и 16 доношенных новорожденных. Содержание сурфактант-ного протеина В в сыворотке крови определяли на 3-5 день жизни иммуноферментным методом с помощью набора "HumanHSP-27 / HSPB1 (HeartShockProtein 27) ELISAkit" (Elabscience) в соответствии с инструкцией фирмы-производителя.Результаты и обсуждение. Исследование уровня SP-B в сыворотке крови детей основной группы показа-ло, что его содержание достоверно выше и составило в среднем 58,5 ± 5,4 нг / мл, тогда как у детей контроль-ной группы среднее значение было 22,06 ± 2,3 нг / мл (p, Introduction. Surfactant protein components are necessary and effective functionality of its parts. The greatest scientific interest among surfactant protein is the study of surfactant protein B. The main functions are to increase the surface tension in the alveoli, anti-inflammatory and antioxidant properties. However, the final idea about its physiological role and content in various pathological conditions, has not yet formed.Materials and methods. Examination 58 newborns, including 42 newborns premature who had respiratory pathology in the neonatal period, average gestational age 32,18 ± 1,4 weeks, average weight at birth 1919,1 ± 123,4 g and 16 term infants . The content of surfactant protein in serum were determined on day 3-5 of life for ELISA set "HumanHSP-27 / HSPB1 (HeartShockProtein 27) ELISAkit" (Elabscience) according to the instructions of the manufacturer.Results and discussion.The level of SP-B in the serum of children of the main group showed significantly higher its content has averaged 58.5 ± 5,4 ng / ml, while children in the control group the average value was 22.06 ± 2,3 ng / ml (p
- Published
- 2016
5. Перинатальные факторы риска формирования бронхиальной астмы у детей
- Author
-
Yablon, O. and Mazulov, O.
- Subjects
бронхиальная астма ,дети ,bronchial asthma ,children ,бронхіальна астма ,діти - Abstract
Бронхіальна астма (БА) є поширеним захворюванням у дітей різних вікових груп, частою причиною інвалідизації дітей. Вивчення механізмів розвитку астми дозволяє дослідити нові напрямки лікування захворювання, а дослідження факторів ризику астми дозволяє зменшити ризик розвитку важких форм захворювання або взагалі попередити розвиток астми. Вивчення факторів ризику, які діють в перинатальному періоді, представляє особливу цікавість з огляду на те, що ці фактори є найчисленнішими в житті немовля та такі, що справляють самий потужний вплив на виникнення та перебіг майбутніх захворювань у дітей. Тому метою нашого дослідження було дослідити вплив перинатальних факторів на розвиток бронхіальної астми у дітей та виявити залежність між впливом цих факторів та важкістю перебігу бронхіальної астми у дітей. Ми провели ретроспективний аналіз 82 історій хвороб та амбулаторних карт дітей, народжених в період 2008-2009 рік та які знаходились на лікуванні в Вінницькій обласній дитячій клінічній лікарні. Діти були розділені на дві групи : контрольна включала в себе 36 дітей без бронхіальної астми та група спостереження з 46 дітей з встановленим діагнозом БА. Дітей, хворих на персистучу форму бронхіальної астми важкого ступеня в нашій виборці не було. Розподіл дітей за статтю був приблизно однаковим. Середній вік дітей склав 5,7± 0,6 роки. Нами було виявлено, що серед екстрагенітальної патології матері достовірно частіше зустрічалися ГРВІ, на другому місці анемія вагітних, на третьому місці перенесений пієлонефрит під час вагітності. В групі дітей з БА побутова сенсибілізація у матерів зустрічалася в 4 рази частіше. Частота гестозу другої половини вагітності в групі спостереження також була достовірно вища. В групі спостереження достовірно частіше проводився кесарів розтин, а ускладнений перебіг пологів зустрічався більше ніж в 5 разів частіше, ніж в контрольній групі. В контрольній групі недоношених дітей не було, в той час як в групі спостереження недоношені діти склали 83,3 %. Аналізуючи недоношених дітей в групі спостереження ми виявили, що серед цих дітей недоношені, які народились терміном менше 32 тижнів склали 58% та недоношені з вагою менше 1500 грам 38%. Також у групі спостереження ми виявили дітей з бронхолегеневою дисплазією, які склали 25% від усіх дітей. Нами також був виявлений зв’язок між прийомом антибактеріальних препаратів в ранньому віці та розвитком БА. У дітей, які хворіли на БА, достовірно частіше проводилася антибіотикотерапія, причому антибіотики не використовувались лише у кожної двадцятої дитини, в той час, коли лише кожна двадцята дитина з групи контролю отримувала один антибактеріальний препарат. Аналізуючи респіраторну підтримку в неонатальному періоді ми виявили, що випадки проведення оксигенотерапії в контрольній групі були відсутні, натомість в групі спостереження лише одна дитина не отримувала певний вид оксигенотерапії. Крім того, нами була виявлена залежність між важкістю БА та тривалістю оксигенотерапії у групі спостереження. Найменша середня тривалість оксигенотерапії спостерігалася у дітей з інтермітуючим перебігом БА та складала 3,39±0,43 днів. При персистуючій БА легкого ступеня важкості середня тривалість оксигенотерапії склала 6,08±1,35 днів, при персистуючій БА середнього ступеня важкості тривалість оксигенотерапії була найдовшою та досягала 7,7±1,45 днів. Отже, нами був виявлений прямий кореляційний зв’язок між недоношеністю та розвитком БА, між прийомом антибіотиків в ранньому віці та розвитком БА, а також залежність між важкістю перебігу бронхіальної астми та тривалістю оксигенотерапії., Бронхиальная астма (БА) является распространенным заболеванием у детей разных возрастных групп, частой причиной инвалидизации детей. Изучение механизмов развития астмы позволяет исследовать новые направления лечения заболевания, а исследования факторов риска астмы позволяет уменьшить риск развития тяжелых форм заболевания или вообще предотвратить развитие астмы. Изучение факторов риска, которые действуют в перинатальном периоде, представляет особый интерес ввиду того, что эти факторы являются самыми многочисленными в жизни младенца и такие, которые оказывают самое сильное влияние на возникновение и течение будущих заболеваний у детей. Поэтому целью нашего исследования было исследовать влияние перинатальных факторов на развитие бронхиальной астмы у детей и выявить зависимость между влиянием этих факторов и тяжестью течения бронхиальной астмы у детей. Мы провели ретроспективный анализ 82 историй болезней и амбулаторных карт детей, рожденных в период 2008-2009 год и которые находились на лечении в Винницкой областной детской клинической больницы. Дети были разделены на две группы: контрольная включала в себя 36 детей без бронхиальной астмы и группа наблюдения из 46 детей с установленным диагнозом БА. Детей, больных персистирующей формой бронхиальной астмы тяжелой степени в нашей избиратели не было. Распределение детей по полу был примерно одинаковым. Средний возраст детей составил 5,7 ± 0,6 года. Нами было выявлено, что среди экстрагенитальной патологии матери достоверно чаще встречались ОРВИ, на втором месте анемия беременных, на третьем месте перенесен пиелонефрит во время беременности. В группе детей с БА бытовая сенсибилизация у матерей встречалась в 4 раза чаще. Частота гестоза второй половины беременности в группе наблюдения также была достоверно выше. В группе наблюдения достоверно чаще проводился кесарево сечение, а осложненное течение родов встречался более чем в 5 раз чаще, чем в контрольной группе. В контрольной группе недоношенных детей не было, в то время как в группе наблюдения недоношенные дети составили 83,3%. Анализируя недоношенных детей в группе наблюдения, мы обнаружили, что среди этих детей недоношенные, родившиеся на срок менее 32 недель составили 58% и недоношенные с весом менее 1500 грамм 38%. Также в группе наблюдения мы обнаружили детей с бронхолегочной дисплазией, которые составили 25% от всех детей. Нами также была обнаружена связь между приемом антибактериальных препаратов в раннем возрасте и развитием БА. У детей, которые болели астмой, достоверно чаще проводилась антибиотикотерапия, причем антибиотики не использовались лишь у каждой двадцатого ребенка, в то время, когда только каждый двадцатый ребенок из группы контроля получал один антибактериальный препарат. Анализируя респираторную поддержку в неонатальном периоде мы обнаружили, что случаи проведения оксигенотерапии в контрольной группе отсутствовали, зато в группе наблюдения лишь один ребенок не получала определенный вид оксигенотерапии. Кроме того, нами была выявлена зависимость между тяжестью БА и продолжительностью оксигенотерапии в группе наблюдения. Наименьшая средняя продолжительность оксигенотерапии наблюдалась у детей с интермиттирующей течением БА и составляла 3,39 ± 0,43 дней. При персистирующей БА легкой степени тяжести средняя продолжительность оксигенотерапии составила 6,08 ± 1,35 дней, при персистирующей БА средней степени тяжести продолжительность оксигенотерапии была длинной и достигала 7,7 ± 1,45 дней. Таким образом, нами был обнаружен прямая корреляционная связь между недоношенностью и развитием БА, между приемом антибиотиков в раннем возрасте и развитием БА, а также зависимость между тяжестью течения бронхиальной астмы и продолжительностью оксигенотерапии., Bronchial asthma (BA) is a common disease in children of different age groups, a common cause of disability in children. Study of developing asthma allows you to explore new areas of treatment of disease and risk factors for asthma research to reduce the risk of severe forms of the disease or even prevent the development of asthma. The study of risk factors that operate in the perinatal period, of particular interest in view of the fact that these factors are most numerous in the life of the baby and those who have a very powerful effect on the occurrence and course of disease in a future. The purpose of our study was investigating the influence of perinatal factors on the development of asthma in children and identify the relationship between these factors influence on course and severity of asthma in children. We conducted a retrospective analysis of 82 case histories of outpatients and children born in the period 2008-2009 and those ,who were treated at the Vinnytsia Oblast Children's Hospital. The children were divided into two groups: control group include 36 children without asthma and observation group of 46 children with diagnosed asthma. The distribution of children by sex was about the same. Children with severe persistent form of asthma in our voters were not. The average age of children was 5,7 ± 0,6 years. We found that among extragenital mother pathology significantly more frequent ARI, followed by anemia pregnant women in third place pyelonephritis during pregnancy. In the group of children with asthma ,consumer sensitization of mothers ,met 4 times more often.The incidence of preeclampsia in the second half of pregnancy observation group was also significantly higher. In the observation group significantly more caesarean section was performed, and complicated childbirth course met more than five times more frequently than in the control group. In the control group of preterm infants was not, while in the group of premature babies observations made 83.3%. Analyzing premature infants in the group observation, we found that among those premature children who were born less than 32 weeks period amounted to 58% of premature and weighing less than 1500 grams of 38%. Also in the observation group, we found children with bronchopulmonary dysplasia, which amounted to 25% of all children. We have also been found a link between taking antibiotics at an early age and the development of asthma. Children who suffered from asthma, was significantly more frequent antibiotic therapy, and interesting that antibiotics are not used only in the every twentieth of child at the time, when only one in twenty children from the control group received a single antibacterial drug. Analyzing respiratory support in the neonatal period, we found that instances of oxygen therapy in the control group were absent, while in the group supervision only one child did not receive a certain type of oxygen therapy. In addition, we have found relationship between asthma severity and duration of oxygen therapy in group supervision. The lowest average duration of oxygen therapy was observed in children with intermittent asthma and was 3,39 ± 0,43 days. If persistent mild asthma severity average duration of oxygen therapy was 6,08 ± 1,35 days, with persistent asthma of medium severity was the longest duration of oxygen therapy and reached 7,7 ± 1,45 days. So, we had found a direct correlation between prematurity and the development of asthma between taking antibiotics at an early age and the development of asthma, as well as the relationship between the severity of asthma course and duration of oxygen therapy.
- Published
- 2015
6. BRAIN-DERIVED NEUROTROPHIC FACTOR: DIAGNOSTIC PERSPECTIVE IN NEONATES WITH GESTATIONAL AGE LESS THAN 34 WEEKS.
- Author
-
Kyslova, Iu., Yablon, O., Mazulov, O., Savrun, T., and Bykovska, O.
- Published
- 2018
7. Perinatal risk factors for asthma development in children
- Author
-
Yablon, O., primary and Mazulov, O., additional
- Published
- 2015
- Full Text
- View/download PDF
8. 1789 Bronchoalveolar Interleukin-1 Beta: A Marker of Bacterial Burden in Long Term Mechanical Ventilation Newborn with Ventilator-Associated Pneumonia
- Author
-
Dmytriiev, D., primary, Katilov, O., additional, Mazulov, O., additional, and Dmytriieva, K., additional
- Published
- 2012
- Full Text
- View/download PDF
9. 1702 Increase Plasma Endothelin-1 Levels are Associated with Lung Hypertension in Low Birth Newborns with Omphalocele
- Author
-
Dmytriiev, D., primary, Katilov, O., additional, Mazulov, O., additional, and Dmytriieva, K., additional
- Published
- 2012
- Full Text
- View/download PDF
10. BRAIN-DERIVED NEUROTROPHIC FACTOR: DIAGNOSTIC PERSPECTIVE IN NEONATES WITH GESTATIONAL AGE LESS THAN 34 WEEKS
- Author
-
Kyslova, Iu, Yablon, O., Mazulov, O., Savrun, T., and Bykovska, O.
11. A case of congenital infantile fibrosarcoma in a newborn
- Author
-
Konoplitskyi, V., Pogorilyi, V., Moravska, O., Dmytro Dmytriiev, Chuhu, T., Fomin, O., Zaletskyi, B., and Mazulov, O.
12. World Bronchiectasis Day: It is time for global action to promote equity of care
- Author
-
KARADAĞ, BÜLENT TANER and Mazulov O., Powell Z., Powell E., Bush A. B., Chang A. B., Kantar A., Grimwood K., KARADAĞ B. T.
- Subjects
Pulmonary and Respiratory Medicine ,QoL ,bronchiectasis ,Sağlık Bilimleri ,Pediatrics ,Clinical Medicine (MED) ,Çocuk Sağlığı ve Hastalıkları ,Child Health and Diseases ,SOLUNUM SİSTEMİ ,cystic fibrosis ,children ,Respiratory Care ,Health Sciences ,Klinik Tıp (MED) ,Chest Diseases and Allergy ,Pediatri, Perinatoloji ve Çocuk Sağlığı ,Internal Medicine Sciences ,Klinik Tıp ,RESPIRATORY SYSTEM ,Dahili Tıp Bilimleri ,Göğüs Hastalıkları ve Allerji ,CLINICAL MEDICINE ,Tıp ,Pediatri ,Pediatrics, Perinatology and Child Health ,Akciğer ve Solunum Tıbbı ,Medicine ,PEDİATRİ ,Solunum Bakımı - Published
- 2023
13. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO.
- Author
-
Papadopoulos NG, Custovic A, Deschildre A, Gern JE, Nieto Garcia A, Miligkos M, Phipatanakul W, Wong G, Xepapadaki P, Agache I, Arasi S, Awad El-Sayed Z, Bacharier LB, Bonini M, Braido F, Caimmi D, Castro-Rodriguez JA, Chen Z, Clausen M, Craig T, Diamant Z, Ducharme FM, Ebisawa M, Eigenmann P, Feleszko W, Fierro V, Fiocchi A, Garcia-Marcos L, Goh A, Gómez RM, Gotua M, Hamelmann E, Hedlin G, Hossny EM, Ispayeva Z, Jackson DJ, Jartti T, Jeseňák M, Kalayci O, Kaplan A, Konradsen JR, Kuna P, Lau S, Le Souef P, Lemanske RF, Levin M, Makela MJ, Mathioudakis AG, Mazulov O, Morais-Almeida M, Murray C, Nagaraju K, Novak Z, Pawankar R, Pijnenburg MW, Pite H, Pitrez PM, Pohunek P, Price D, Priftanji A, Ramiconi V, Rivero Yeverino D, Roberts G, Sheikh A, Shen KL, Szepfalusi Z, Tsiligianni I, Turkalj M, Turner S, Umanets T, Valiulis A, Vijveberg S, Wang JY, Winders T, Yon DK, Yusuf OM, and Zar HJ
- Subjects
- Humans, Child, Quality of Life, Anti-Asthmatic Agents therapeutic use, Delphi Technique, Monitoring, Physiologic methods, Asthma diagnosis, Asthma therapy
- Abstract
Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even "real-time," monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design., (© 2024 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
14. A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study.
- Author
-
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Collaro AJ, Chalmers JD, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, and Grimwood K
- Subjects
- Adolescent, Child, Humans, Delphi Technique, Outcome Assessment, Health Care, Research Design, Systematic Reviews as Topic, Treatment Outcome, Consensus, Bronchiectasis therapy, Quality of Life
- Abstract
Improving the treatment of non-cystic fibrosis bronchiectasis in children and adolescents requires high-quality research with outcomes that meet study objectives and are meaningful for patients and their parents and caregivers. In the absence of systematic reviews or agreement on the health outcomes that should be measured in paediatric bronchiectasis, we established an international, multidisciplinary panel of experts to develop a core outcome set (COS) that incorporates patient and parent perspectives. We undertook a systematic review from which a list of 21 outcomes was constructed; these outcomes were used to inform the development of separate surveys for ranking by parents and patients and by health-care professionals. 562 participants (201 parents and patients from 17 countries, 361 health-care professionals from 58 countries) completed the surveys. Following two consensus meetings, agreement was reached on a ten-item COS with five outcomes that were deemed to be essential: quality of life, symptoms, exacerbation frequency, non-scheduled health-care visits, and hospitalisations. Use of this international consensus-based COS will ensure that studies have consistent, patient-focused outcomes, facilitating research worldwide and, in turn, the development of evidence-based guidelines for improved clinical care and outcomes. Further research is needed to develop validated, accessible measurement instruments for several of the outcomes in this COS., Competing Interests: Declaration of interests ABC is a member of the independent data management committees for clinical trials for Moderna (COVID-19 vaccine), GSK (an unlicensed vaccine), and AstraZeneca (a monoclonal antibody); she also reports payments to her institution for consulting on study designs for Zambon and Boehringer Ingelheim, travel expenses from the European Respiratory Society and Boehringer Ingelheim, and personal fees for authorship of two UpToDate chapters, outside of the submitted work. AZ reports personal fees for lectures from AstraZeneca, Chiesi, Vertex Pharmaceuticals, and Sanofi, and travel fees from Vertex, outside of the submitted work. JDC reports personal consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Insmed, Grifols, Pfizer, Jansen, Antabio, and Zambon, outside of the submitted work but related to bronchiectasis in adults; he also reports grants from AstraZeneca, Boehringer Ingelheim, Novartis, GSK, Gilead Sciences, Insmed, Grifols, and Genentech, outside of the submitted work but related to bronchiectasis in adults. MG reports personal consulting fees and honoraria for lectures and presentations and for advice on an adjudication board from Boehringer Ingelheim and for advice on study development from Roche, outside of the submitted work. JG reports unrestricted grants from OM Pharma and Mariomed Biotech, and receipt of wheeze-detection equipment without cost from OMRON; he also reports personal fees for advisory board membership from OM Pharma, GSK, and AstraZeneca, for his role as a chief investigator on an asthma study from AstraZeneca, for lectures from Sanofi, and for expert testimony for medical advice, outside of the submitted work. AM reports grants to his institution from Vertex. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Developments and priorities in bronchiectasis research.
- Author
-
Mazulov O, Hill AT, and Marchant J
- Subjects
- Humans, Biomedical Research trends, Bronchiectasis therapy
- Abstract
Competing Interests: JM reports grants from the National Health and Medical Research Council and the Medical Research Futures Fund, Australia, and personal fees for authorship of two UpToDate chapters, outside of the submitted work. OM and ATH declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
16. World Bronchiectasis Day: It is time for global action to promote equity of care.
- Author
-
Mazulov O, Powell Z, Powell E, Bush A, Chang AB, Kantar A, Grimwood K, and Karadag B
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Bronchiectasis therapy, Bronchiectasis drug therapy
- Published
- 2023
- Full Text
- View/download PDF
17. European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials.
- Author
-
Chang AB, Zacharasiewicz A, Goyal V, Boyd J, Alexopoulou E, Aliberti S, Bell L, Bush A, Claydon A, Constant C, Fortescue R, Hill AT, Karadag B, Powell Z, Wilson C, Grimwood K, Kantar A, Chalmers J, Collaro A, Douros K, Griese M, Grigg J, Hector A, Mazulov O, Midulla F, Möller A, Proesmans M, and Yerkovich S
- Subjects
- Adult, Adolescent, Child, Humans, Quality of Life, Respiratory System, Outcome Assessment, Health Care, Anti-Bacterial Agents therapeutic use, Bronchiectasis therapy, Bronchiectasis drug therapy
- Abstract
Bronchiectasis is being diagnosed increasingly in children and adolescents. Recurrent respiratory exacerbations are common in children and adolescents with this chronic pulmonary disorder. Respiratory exacerbations are associated with an impaired quality of life, poorer long-term clinical outcomes, and substantial costs to the family and health systems. The 2021 European Respiratory Society (ERS) clinical practice guideline for the management of children and adolescents with bronchiectasis provided a definition of acute respiratory exacerbations for clinical use but to date there is no comparable universal definition for clinical research. Given the importance of exacerbations in the field, this ERS Task Force sought to obtain robust definitions of respiratory exacerbations for clinical research. The panel was a multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, methodology, patient advocacy, and parents of children and adolescents with bronchiectasis. We used a standardised process that included a systematic literature review, parent survey, and a Delphi approach involving 299 physicians (54 countries) caring for children and adolescents with bronchiectasis. Consensus was obtained for all four statements drafted by the panel as the disagreement rate was very low (range 3.6-7.2%). The panel unanimously endorsed the four consensus definitions for 1a) non-severe exacerbation and 1b) severe exacerbation as an outcome measure, 2) non-severe exacerbation for studies initiating treatment, and 3) resolution of a non-severe exacerbation for clinical trials involving children and adolescents with bronchiectasis. This ERS Task Force proposes using these internationally derived, consensus-based definitions of respiratory exacerbations for future clinical paediatric bronchiectasis research., Competing Interests: Conflict of Interest: E. Alexopoulou, L. Bell, A. Bush, C. Constant, R. Fortescue, B. Karadag, A.T. Hill, A. Kantar, V. Goyal, A. Zacharasiewicz, J. Boyd, A. Claydon, Z. Powell and C. Wilson have nothing to disclose. A.B. Chang reports grants from National Health and Medical Research Council, Australia, during the conduct of the study; is IDMC member for an unlicensed vaccine (GSK), is advisory member of study design for an unlicensed molecule for chronic cough (Merck), and is IDMC member for an unlicensed monoclonal antibody (AstraZeneca); and has received personal fees from being an author of two UpToDate chapters, outside the submitted work. K. Grimwood reports grants from Australian National Health and Medical Research Council, and Medical Research Futures Fund, during the conduct of the study. S. Aliberti reports grants and personal fees from AstraZeneca, Insmed, Fisher & Paykel and Chiesi, and personal fees from GlaxoSmithKline, Gilead Sciences, Novartis, MENARINI, Fondazione Charta, Grifols, Boehringer Ingelheim and Zambon, outside the submitted work., (Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2022
- Full Text
- View/download PDF
18. Quality standards for managing children and adolescents with bronchiectasis: an international consensus.
- Author
-
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Chalmers JD, Collaro AJ, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, and Grimwood K
- Abstract
The global burden of bronchiectasis in children and adolescents is being recognised increasingly. However, marked inequity exists between, and within, settings and countries for resources and standards of care afforded to children and adolescents with bronchiectasis compared with those with other chronic lung diseases. The European Respiratory Society (ERS) clinical practice guideline for the management of bronchiectasis in children and adolescents was published recently. Here we present an international consensus of quality standards of care for children and adolescents with bronchiectasis based upon this guideline. The panel used a standardised approach that included a Delphi process with 201 respondents from the parents and patients' survey, and 299 physicians (across 54 countries) who care for children and adolescents with bronchiectasis. The seven quality standards of care statements developed by the panel address the current absence of quality standards for clinical care related to paediatric bronchiectasis. These internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards statements can be used by parents and patients to access and advocate for quality care for their children and themselves, respectively. They can also be used by healthcare professionals to advocate for their patients, and by health services as a monitoring tool, to help optimise health outcomes., Competing Interests: Conflict of interest: E. Alexopoulou, A. Bush, C. Constant, K. Douros, R. Fortescue, M. Griese, A. Hector, B. Karadag, A.T. Hill, A. Kantar, O. Mazulov, F. Midulla, A. Moeller, M. Proesmans, S.T. Yerkovich, A. Zacharasiewicz, Z. Powell, C. Wilson and A.J. Collaro have nothing to disclose. J. Boyd is an employee of the European Lung Foundation. A.B. Chang reports grants from National Health and Medical Research Council, Australia, during the conduct of the study; monies provided to institution from IDMC Membership of unlicensed products (GSK, AstraZeneca), and vaccine (Moderna), other from Advisory member of study design for unlicensed molecules for chronic cough or bronchiectasis (Merck, Zambon, Boehringer Ingelheim); personal fees from being an author of two UpToDate chapters, outside the submitted work. J.D. Chalmers reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work. J. Grigg reports grants and personal fees from OM Pharma, personal fees from GSK, personal fees from Novartis, personal fees from Omron, personal fees from Astra Zeneca, outside the submitted work. K. Grimwood reports grants from Australian National Health and Medical Research Council and the Australian Medical Research Future Fund during the conduct of the study., (Copyright ©ERS 2022.)
- Published
- 2022
- Full Text
- View/download PDF
19. International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net.
- Author
-
Chang AB, Boyd J, Bush A, Hill AT, Powell Z, Zacharasiewicz A, Alexopoulou E, Chalmers JD, Collaro AJ, Constant C, Douros K, Fortescue R, Griese M, Grigg J, Hector A, Karadag B, Mazulov O, Midulla F, Moeller A, Proesmans M, Wilson C, Yerkovich ST, Kantar A, and Grimwood K
- Subjects
- Adolescent, Consensus, Family, Humans, Reference Standards, Bronchiectasis therapy
- Abstract
Competing Interests: Conflict of interest: E. Alexopoulou, A. Bush, A.J. Collaro, C. Constant, K. Douros, R. Fortescue, M. Griese, K. Grimwood, A. Hector, A.T. Hill, A. Kantar, B. Karadag, O. Mazulov, F. Midulla, A. Moeller, Z. Powell, M. Proesmans, C. Wilson, S.T. Yerkovich and A. Zacharasiewicz have nothing to disclose. A.B. Chang reports grants from the National Health and Medical Research Council, Australia, during the conduct of the study; is an IDMC member for an unlicensed vaccine (GSK) and an unlicensed monoclonal antibody (AstraZeneca); is an advisory member of study design for an unlicensed molecule for chronic cough (Merck); and reports personal fees from being an author of two UpToDate chapters, all outside the submitted work. J. Boyd is an employee of the European Lung Foundation. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, and grants from Gilead Sciences, outside the submitted work. J. Grigg reports grants and personal fees from OM Pharma, and personal fees from GSK, Novartis, Omron and AstraZeneca, outside the submitted work.
- Published
- 2022
- Full Text
- View/download PDF
20. Summer schools of adult and paediatric respiratory medicine: course report.
- Author
-
Loukides S, Kovacs G, Bentata K, Huyền T, Shah BK, Mazulov O, and Eber E
- Abstract
The @EuroRespSoc summers schools of adult and paediatric respiratory medicine took place on June 12-15, 2019, in Barcelona, Spain http://bit.ly/38VPAc5., Competing Interests: Conflict of interest: S. Loukides has nothing to disclose. Conflict of interest: G. Kovacs reports personal fees and nonfinancial support from Actelion, Bayer, GSK, MSD, Boehringer Ingelheim, Novartis, Chiesi and Vitalaire outside the submitted work. Conflict of interest: K. Bentata has nothing to disclose. Conflict of interest: T. Thanh Huyền has nothing to disclose. Conflict of interest: K. Shah has nothing to disclose. Conflict of interest: O. Mazulov has nothing to disclose. Conflict of interest: E. Eber has nothing to disclose., (Copyright ©ERS 2020.)
- Published
- 2020
- Full Text
- View/download PDF
21. A case of congenital infantile fibrosarcoma in a newborn.
- Author
-
Konoplitskyi V, Pogorilyi V, Moravska O, Dmytriiev D, Chuhu T, Fomin O, Zaletskyi B, and Mazulov O
- Subjects
- Humans, Infant, Newborn, Soft Tissue Neoplasms congenital, Fibrosarcoma congenital
- Abstract
Infantile fibrosarcoma is a malignant tumor, which is most common in infants, preferentially localized in the lower limbs. An important prognostic factor of the disease is early diagnostics, both clinical and instrumental. The operative treatment of infantile fibrosarcoma is a leading treatment method. The article describes a clinical case of infantile fibrosarcoma in a newborn with fetal development of the disease.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.